Drug intelligence / Profile preview

TaiYi

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

TaiYi is a domestic (Chinese) generic version of ticagrelor, an antiplatelet drug that was approved in China in August 2018. It is indicated for antiplatelet aggregation in patients with coronary atherosclerotic heart disease, particularly those undergoing percutaneous coronary intervention. As a P2Y12 receptor antagonist, TaiYi functions by reversibly inhibiting platelet aggregation, thereby reducing the risk of thrombotic events.

Brand names: TaiYi
Other names: 口服泰仪

Targets

P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on TaiYi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TaiYi.

Explore the full profile